Case report of a 19-year-old patient with β-thalassemia major, type 1 diabetes mellitus, osteoporosis and other major complications
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250725Keywords:
Thalassemia major, β-thalassemia, Osteoporosis, Blood transfusion, Hemoglobinopathies, Thalassemia minor, Thalassemia intermediaAbstract
This case report presents a detailed clinical profile of a 19-year-old male with β-thalassemia major, highlighting the multi-system complications associated with long-term disease management and chronic transfusion therapy. Diagnosed at one year of age due to symptoms including poor feeding, irritability, developmental delays, and failure to thrive, the patient’s haemoglobin electrophoresis showed markedly elevated HbF levels, confirming β-thalassemia major. Over the years, the patient has undergone regular transfusions and a splenectomy at age seven to address hypersplenism. Family screening in 2014 identified β-thalassemia trait in both parents and three siblings, prompting genetic counselling. In 2020, the patient developed diabetic ketoacidosis, presenting with hyperglycaemia and ketonuria, and was subsequently diagnosed with type 1 diabetes mellitus, managed with insulin therapy. By 2023, he exhibited signs of iron overload, with MRI showing iron deposition across multiple organs and serum ferritin levels exceeding 2000 ng/mL. Additional findings included hepatomegaly, mild pleural effusion, thyroid dysfunction, and osteoporosis confirmed by bone mineral density testing. Current management includes oral deferasirox for iron chelation, calcium and vitamin D supplementation, folic acid, and insulin therapy tailored to his glucose needs.
Metrics
References
Mahajan PS, Kolleri JJ, Ait Souabni S, Prasad S, Belhaddad EH, Mohammed H. Report of a rare case of beta-thalassemia major with subperiosteal hematomas. Cureus. 2022;14(4):23770. DOI: https://doi.org/10.7759/cureus.23770
Bajwa H, Basit H. Thalassemia. Stat Pearls. Treasure Island (FL): Stat Pearls Publishing. 2024.
Galanello R, Origa R. Beta-thalassemia. Orph J Rare Dis. 2010;5:1-5. DOI: https://doi.org/10.1186/1750-1172-5-11
Mahgoub EO, Qannita R, Alalami A, Al Shehadat O, Al Mahmoud R, Dib A, et al. Diabetes mellitus progression in β-thalassaemia major patients: The impact of iron overload. Adv Biomed Health Sci. 2024;3(1):5-12. DOI: https://doi.org/10.4103/abhs.abhs_39_23
Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A. Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience. J Clin Res Pediat Endocrinol. 2019;11(2):110. DOI: https://doi.org/10.4274/jcrpe.galenos.2018.2018.0074
Langer AL. Beta-Thalassemia. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle 1993-2024. 2002. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 21 September 2024.
Origa R. β-Thalassemia. Genetics in medicine. 2017;19(6):609-19. DOI: https://doi.org/10.1038/gim.2016.173
Chatterjee R, Bajoria R. New concept in natural history and management of diabetes mellitus in thalassemia major. Hemoglobin. 2009;33(1):127-30. DOI: https://doi.org/10.3109/09553000903347880
Bhardwaj A, Swe KM, Sinha NK. Treatment for osteoporosis in people with beta‐thalassaemia. Cochrane Database of Systematic Reviews. 2023(5).10429. DOI: https://doi.org/10.1002/14651858.CD010429.pub3
Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. International Journal of laboratory hematology. 2016;38:32-40. DOI: https://doi.org/10.1111/ijlh.12527
Rivella S. β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100(4):418. DOI: https://doi.org/10.3324/haematol.2014.114827
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-8. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.874487
Aydinok Y, Kattamis A, Cappellini MD. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;125(25):3868–77. DOI: https://doi.org/10.1182/blood-2014-07-586677
Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Gen. 2014;46(7):678–84. DOI: https://doi.org/10.1038/ng.2996
Ginzburg Y, Rivella S. Β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321–30. DOI: https://doi.org/10.1182/blood-2011-03-283614
Sharma A, Easow Mathew M, Puri L. Splenectomy for people with thalassaemia major or intermedia. The Cochr Dat Sys Rev. 2019;9(9):10517. DOI: https://doi.org/10.1002/14651858.CD010517.pub3
Gaziev J. Bone marrow transplantation for thalassemia from alternative related donors: Improved outcomes with a new approach. Blood. 2013;122(15):2751-6. DOI: https://doi.org/10.1182/blood-2013-07-513473